The use of propranolol in the management of periocular capillary haemangioma—a systematic review
Capillary haemangioma or infantile haemangioma (IH) is the most common congenital vascular tumour in the periocular region. Several treatment modalities have been documented, with variable degree of success. Propranolol has recently been reported to be an effective and safe alternative. The aim of t...
Gespeichert in:
| Veröffentlicht in: | Eye (London) 2011-10, Vol.25 (10), p.1277-1283 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1283 |
|---|---|
| container_issue | 10 |
| container_start_page | 1277 |
| container_title | Eye (London) |
| container_volume | 25 |
| creator | Spiteri Cornish, K Reddy, A R |
| description | Capillary haemangioma or infantile haemangioma (IH) is the most common congenital vascular tumour in the periocular region. Several treatment modalities have been documented, with variable degree of success. Propranolol has recently been reported to be an effective and safe alternative. The aim of this systematic review is to examine the evidence base for the use of propranolol administered orally in the management of periocular capillary haemangioma, and use this information to guide future research. A systematic review of literature was carried out by two independent reviewers using the search strategies highlighted below. A total of 100 cases of oral propranolol use in periorbital or orbital capillary haemangiomas have been documented in the literature. Of the 85 cases that had details of previous treatment, it was used as first-line treatment in 50 (58.8%). The commonest dose used was 2 mg/kg/day. Adverse events were documented in one-third of cases; in most cases these were minor. Improvement or complete resolution of the lesions occurred in 96% of cases. Recurrence was noted in one-fifth of cases. Propranolol has shown a lot of promise in the therapy of IH and further research in the form of properly designed randomized trials is certainly warranted. Treatment guidelines based on literature available to date is included in this review. |
| doi_str_mv | 10.1038/eye.2011.164 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3194317</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2483880171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-6cd839f459aaf923aadf86ea7b9b83e0a00ed04636d7ed207f2cd78261e8253a3</originalsourceid><addsrcrecordid>eNptkc1u1DAUhS1ERacDO9bIQmJHBv8ldjZIqCoFqVI3RWJn3XFuZlwlcbCTotnxEH1CngQPM7QgsfKVz6d7ju4h5CVnK86keYc7XAnG-YpX6glZcKWrolSlekoWrC5ZIYT4ekrOUrplLIuaPSOngmtphJQLsr7ZIp0T0tDSMYYxwhC60FE_0CkrPQywwR6H6TeA0Qc3dxCpg9F3edjRLWCmNj708PPHPdC0S1P-mbyjEe88fn9OTlroEr44vkvy5ePFzfmn4ur68vP5h6vCKW2monKNkXWryhqgrYUEaFpTIeh1vTYSGTCGDVOVrBqNjWC6Fa7RRlQcjSglyCV5f9g7zuseG5dDR-jsGH2fc9oA3v6rDH5rN-HOSl4rmS-yJK-PC2L4NmOa7G2Y45AzW1Nrkw_G9tDbA-RiSCli-2DAmd0XYnMhdl-IzYVk_NXfoR7gPw1k4M0RgOSga3MBzqdHTlV1LczetzhwKUvDBuNjuP8a_wLdkKZO</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>897882307</pqid></control><display><type>article</type><title>The use of propranolol in the management of periocular capillary haemangioma—a systematic review</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Spiteri Cornish, K ; Reddy, A R</creator><creatorcontrib>Spiteri Cornish, K ; Reddy, A R</creatorcontrib><description>Capillary haemangioma or infantile haemangioma (IH) is the most common congenital vascular tumour in the periocular region. Several treatment modalities have been documented, with variable degree of success. Propranolol has recently been reported to be an effective and safe alternative. The aim of this systematic review is to examine the evidence base for the use of propranolol administered orally in the management of periocular capillary haemangioma, and use this information to guide future research. A systematic review of literature was carried out by two independent reviewers using the search strategies highlighted below. A total of 100 cases of oral propranolol use in periorbital or orbital capillary haemangiomas have been documented in the literature. Of the 85 cases that had details of previous treatment, it was used as first-line treatment in 50 (58.8%). The commonest dose used was 2 mg/kg/day. Adverse events were documented in one-third of cases; in most cases these were minor. Improvement or complete resolution of the lesions occurred in 96% of cases. Recurrence was noted in one-fifth of cases. Propranolol has shown a lot of promise in the therapy of IH and further research in the form of properly designed randomized trials is certainly warranted. Treatment guidelines based on literature available to date is included in this review.</description><identifier>ISSN: 0950-222X</identifier><identifier>EISSN: 1476-5454</identifier><identifier>DOI: 10.1038/eye.2011.164</identifier><identifier>PMID: 21738233</identifier><identifier>CODEN: EYEEEC</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1484 ; 692/699/67/1059/99 ; Administration, Oral ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Child, Preschool ; Disease Progression ; Evidence-Based Medicine ; Female ; Hemangioma, Capillary - congenital ; Hemangioma, Capillary - drug therapy ; Hemangioma, Capillary - physiopathology ; Humans ; Infant ; Infant, Newborn ; Laboratory Medicine ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Miscellaneous ; Ophthalmology ; Orbital Neoplasms - congenital ; Orbital Neoplasms - drug therapy ; Orbital Neoplasms - physiopathology ; Pharmaceutical Sciences/Technology ; Propranolol - administration & dosage ; Propranolol - adverse effects ; Propranolol - therapeutic use ; Review ; Surgery ; Surgical Oncology ; Treatment Outcome</subject><ispartof>Eye (London), 2011-10, Vol.25 (10), p.1277-1283</ispartof><rights>Royal College of Ophthalmologists 2011</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Oct 2011</rights><rights>Copyright © 2011 Royal College of Ophthalmologists 2011 Royal College of Ophthalmologists</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-6cd839f459aaf923aadf86ea7b9b83e0a00ed04636d7ed207f2cd78261e8253a3</citedby><cites>FETCH-LOGICAL-c478t-6cd839f459aaf923aadf86ea7b9b83e0a00ed04636d7ed207f2cd78261e8253a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194317/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194317/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24699287$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21738233$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Spiteri Cornish, K</creatorcontrib><creatorcontrib>Reddy, A R</creatorcontrib><title>The use of propranolol in the management of periocular capillary haemangioma—a systematic review</title><title>Eye (London)</title><addtitle>Eye</addtitle><addtitle>Eye (Lond)</addtitle><description>Capillary haemangioma or infantile haemangioma (IH) is the most common congenital vascular tumour in the periocular region. Several treatment modalities have been documented, with variable degree of success. Propranolol has recently been reported to be an effective and safe alternative. The aim of this systematic review is to examine the evidence base for the use of propranolol administered orally in the management of periocular capillary haemangioma, and use this information to guide future research. A systematic review of literature was carried out by two independent reviewers using the search strategies highlighted below. A total of 100 cases of oral propranolol use in periorbital or orbital capillary haemangiomas have been documented in the literature. Of the 85 cases that had details of previous treatment, it was used as first-line treatment in 50 (58.8%). The commonest dose used was 2 mg/kg/day. Adverse events were documented in one-third of cases; in most cases these were minor. Improvement or complete resolution of the lesions occurred in 96% of cases. Recurrence was noted in one-fifth of cases. Propranolol has shown a lot of promise in the therapy of IH and further research in the form of properly designed randomized trials is certainly warranted. Treatment guidelines based on literature available to date is included in this review.</description><subject>631/67/1484</subject><subject>692/699/67/1059/99</subject><subject>Administration, Oral</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Child, Preschool</subject><subject>Disease Progression</subject><subject>Evidence-Based Medicine</subject><subject>Female</subject><subject>Hemangioma, Capillary - congenital</subject><subject>Hemangioma, Capillary - drug therapy</subject><subject>Hemangioma, Capillary - physiopathology</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Laboratory Medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Miscellaneous</subject><subject>Ophthalmology</subject><subject>Orbital Neoplasms - congenital</subject><subject>Orbital Neoplasms - drug therapy</subject><subject>Orbital Neoplasms - physiopathology</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Propranolol - administration & dosage</subject><subject>Propranolol - adverse effects</subject><subject>Propranolol - therapeutic use</subject><subject>Review</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Treatment Outcome</subject><issn>0950-222X</issn><issn>1476-5454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNptkc1u1DAUhS1ERacDO9bIQmJHBv8ldjZIqCoFqVI3RWJn3XFuZlwlcbCTotnxEH1CngQPM7QgsfKVz6d7ju4h5CVnK86keYc7XAnG-YpX6glZcKWrolSlekoWrC5ZIYT4ekrOUrplLIuaPSOngmtphJQLsr7ZIp0T0tDSMYYxwhC60FE_0CkrPQywwR6H6TeA0Qc3dxCpg9F3edjRLWCmNj708PPHPdC0S1P-mbyjEe88fn9OTlroEr44vkvy5ePFzfmn4ur68vP5h6vCKW2monKNkXWryhqgrYUEaFpTIeh1vTYSGTCGDVOVrBqNjWC6Fa7RRlQcjSglyCV5f9g7zuseG5dDR-jsGH2fc9oA3v6rDH5rN-HOSl4rmS-yJK-PC2L4NmOa7G2Y45AzW1Nrkw_G9tDbA-RiSCli-2DAmd0XYnMhdl-IzYVk_NXfoR7gPw1k4M0RgOSga3MBzqdHTlV1LczetzhwKUvDBuNjuP8a_wLdkKZO</recordid><startdate>20111001</startdate><enddate>20111001</enddate><creator>Spiteri Cornish, K</creator><creator>Reddy, A R</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20111001</creationdate><title>The use of propranolol in the management of periocular capillary haemangioma—a systematic review</title><author>Spiteri Cornish, K ; Reddy, A R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-6cd839f459aaf923aadf86ea7b9b83e0a00ed04636d7ed207f2cd78261e8253a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>631/67/1484</topic><topic>692/699/67/1059/99</topic><topic>Administration, Oral</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Child, Preschool</topic><topic>Disease Progression</topic><topic>Evidence-Based Medicine</topic><topic>Female</topic><topic>Hemangioma, Capillary - congenital</topic><topic>Hemangioma, Capillary - drug therapy</topic><topic>Hemangioma, Capillary - physiopathology</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Laboratory Medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Miscellaneous</topic><topic>Ophthalmology</topic><topic>Orbital Neoplasms - congenital</topic><topic>Orbital Neoplasms - drug therapy</topic><topic>Orbital Neoplasms - physiopathology</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Propranolol - administration & dosage</topic><topic>Propranolol - adverse effects</topic><topic>Propranolol - therapeutic use</topic><topic>Review</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Spiteri Cornish, K</creatorcontrib><creatorcontrib>Reddy, A R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Eye (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Spiteri Cornish, K</au><au>Reddy, A R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The use of propranolol in the management of periocular capillary haemangioma—a systematic review</atitle><jtitle>Eye (London)</jtitle><stitle>Eye</stitle><addtitle>Eye (Lond)</addtitle><date>2011-10-01</date><risdate>2011</risdate><volume>25</volume><issue>10</issue><spage>1277</spage><epage>1283</epage><pages>1277-1283</pages><issn>0950-222X</issn><eissn>1476-5454</eissn><coden>EYEEEC</coden><abstract>Capillary haemangioma or infantile haemangioma (IH) is the most common congenital vascular tumour in the periocular region. Several treatment modalities have been documented, with variable degree of success. Propranolol has recently been reported to be an effective and safe alternative. The aim of this systematic review is to examine the evidence base for the use of propranolol administered orally in the management of periocular capillary haemangioma, and use this information to guide future research. A systematic review of literature was carried out by two independent reviewers using the search strategies highlighted below. A total of 100 cases of oral propranolol use in periorbital or orbital capillary haemangiomas have been documented in the literature. Of the 85 cases that had details of previous treatment, it was used as first-line treatment in 50 (58.8%). The commonest dose used was 2 mg/kg/day. Adverse events were documented in one-third of cases; in most cases these were minor. Improvement or complete resolution of the lesions occurred in 96% of cases. Recurrence was noted in one-fifth of cases. Propranolol has shown a lot of promise in the therapy of IH and further research in the form of properly designed randomized trials is certainly warranted. Treatment guidelines based on literature available to date is included in this review.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>21738233</pmid><doi>10.1038/eye.2011.164</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-222X |
| ispartof | Eye (London), 2011-10, Vol.25 (10), p.1277-1283 |
| issn | 0950-222X 1476-5454 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3194317 |
| source | MEDLINE; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | 631/67/1484 692/699/67/1059/99 Administration, Oral Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Child, Preschool Disease Progression Evidence-Based Medicine Female Hemangioma, Capillary - congenital Hemangioma, Capillary - drug therapy Hemangioma, Capillary - physiopathology Humans Infant Infant, Newborn Laboratory Medicine Male Medical sciences Medicine Medicine & Public Health Miscellaneous Ophthalmology Orbital Neoplasms - congenital Orbital Neoplasms - drug therapy Orbital Neoplasms - physiopathology Pharmaceutical Sciences/Technology Propranolol - administration & dosage Propranolol - adverse effects Propranolol - therapeutic use Review Surgery Surgical Oncology Treatment Outcome |
| title | The use of propranolol in the management of periocular capillary haemangioma—a systematic review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T22%3A48%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20use%20of%20propranolol%20in%20the%20management%20of%20periocular%20capillary%20haemangioma%E2%80%94a%20systematic%20review&rft.jtitle=Eye%20(London)&rft.au=Spiteri%20Cornish,%20K&rft.date=2011-10-01&rft.volume=25&rft.issue=10&rft.spage=1277&rft.epage=1283&rft.pages=1277-1283&rft.issn=0950-222X&rft.eissn=1476-5454&rft.coden=EYEEEC&rft_id=info:doi/10.1038/eye.2011.164&rft_dat=%3Cproquest_pubme%3E2483880171%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=897882307&rft_id=info:pmid/21738233&rfr_iscdi=true |